New Subcutaneous Administration Provides another Mode of Delivery For Patients with Primary Immunodeficiency RESEARCH TRIANGLE PARK , N.C., Oct 14, 2010 /PRNewswire via COMTEX/ -- Talecris ...
RESEARCH TRIANGLE PARK, N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results